Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus + Bevacizumab in Refractory MPNST
NCT01661283Phase 2Completed
- Sponsor
- Sarcoma Alliance for Research through Collaboration
- Start
- Sep 2012
- Primary completion
- Jun 2017
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of everolimus, bevacizumab in malignant peripheral nerve sheath tumor (MPNST), sponsored by Sarcoma Alliance for Research through Collaboration. Started Sep 2012; status: completed.
02
Drugs
everolimusbevacizumab
03
Conditions
malignant peripheral nerve sheath tumor (MPNST)
Beyond the preview
Go deeper on NCT01661283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01661283.